A total of 29 new blockbuster-in-waiting drugs entered the late-stage pipeline in 2024, a jump from the previous year’s 19.

However, if GLP-1RA drugs are excluded from the calculation, this number drops to $370m – indicating their substantial market influence. Among the 20 assets that had their peak sales forecast by ...

Patients without diabetes using GLP-1RAs are less likely to develop glaucoma compared with those who use other weight loss therapies.

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

The use of GLP-1 receptor agonists, like semaglutide, to treat type 2 diabetes is not associated with an increased risk of ...

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Could a diabetes drug slash your cancer risk ... One analysis compared GLP-1RA recipients to metformin recipients, and another compared the former to those taking insulin. Study groups were ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...